Concentrating highly potent warheads in the tumour microenvironment

The Avacta pre|CISIONTM platform is a proprietary warhead delivery system based on a tumour-specific protease that is designed to concentrate highly potent warheads in the tumour microenvironment while sparing normal tissues.

Fibroblast activation protein-α (FAP) is an extracellular post-proline protease that is upregulated in many solid tumours in a membrane-bound form on cancer associated fibroblasts as well as tumour cells. FAP activity is also observed as a soluble protease to a low degree in plasma.

A pre|CISIONTM molecule has two key properties:

  1. It prevents the warhead from entering cells.
  2. It is specifically cleaved by FAP to release active warhead in the tumour.

The peptide moiety linker, pre|CISION™, prevents cellular entry of the warhead unless it is cleaved by FAP, thus enabling targeted delivery of the warhead to tumours.

The first of the pre|CISION molecules, AVA6000, has achieved clinical proof-of-concept.


pre|CISIONTM can be utilised in multiple drug formats:

pre|CISION drug conjugate (PDC)

The warhead is linked to a peptide specifically cleaved by fibroblast activation protein-α (FAP), thus releasing the warhead in the extracellular space of the TME

Read more

pre|CISION+ immuno-peptide drug conjugate

The peptide-warhead conjugate is linked to a biologic such as the Fc region, producing a pre|CISION molecule protected from rapid clearance with warhead cleavage specifically enabled by FAP

Read more

pre|CISION ADC drug conjugate (AffDC)

The peptide-warhead conjugate is linked  to a tumour antigen-targeted monoclonal antibody or Affimer®, creating a highly tumour-specific ADC

Read more

Discover pre|CISIONTM technology – watch the Mechanism of Action video below.

Connect with us

Get in touch to discover our therapeutic technology platforms.

Read More

Partner with us

Get in touch to discuss partnering opportunities.

Read more

Request a meeting

Contact us to request a meeting.

Read more